Evolus (EOLS) Share-based Compensation Growth (1y) (2018 - 2026)
Evolus (EOLS) Share-based Compensation Growth (1y) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 26.47% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 47.06% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 8.79% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 281.05% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 92.83% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 5.49% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 61.54% |
| 10 | Evolus | 390.47 Mn | 340.68 Mn | 48.90 Mn | -13.70% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -13.70% |
| Dec 31, 2025 | 3.31% |
| Sep 30, 2025 | -1.63% |
| Jun 30, 2025 | -22.41% |
| Mar 31, 2025 | 16.72% |
| Dec 31, 2024 | -51.94% |
| Sep 30, 2024 | 13.58% |
| Jun 30, 2024 | 38.67% |
| Mar 31, 2024 | 54.19% |
| Sep 30, 2023 | 177.40% |
| Jun 30, 2023 | 40.01% |
| Mar 31, 2023 | 11.32% |
| Sep 30, 2022 | -339.82% |
| Jun 30, 2022 | 4.12% |
| Mar 31, 2022 | 86.10% |
| Dec 31, 2021 | 0.72% |
| Sep 30, 2021 | -16.12% |
| Jun 30, 2021 | 20.51% |
| Mar 31, 2021 | -39.50% |
| Dec 31, 2020 | 285.87% |